Beyfortus (nirsevimab) Now Available Through VFC
Beyfortus (nirsevimab) Now Available Through VFC On July 17, 2023, FDA licensed AstraZeneca and Sanofi’s Beyfortus (nirsevimab) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD). On August 3, the ACIP voted unanimously to recommend nirsevimab for use in infants during the RSV...